Gileads Idelalisib Encourages Zacks.com Interim analysis of the randomized, double-blind, placebo-controlled study revealed that patients treated with idelalisib plus Roche's (RHHBY) Rituxan (rituximab) exhibited statistically significant improvement in progression free survival compared to ... |
